Literature DB >> 24426753

Total oesophagectomy for squamous cell carcinoma with or without standard two field node dissection - a prospective study.

Shishir V Shah1, Yogen Pavinchandra Chheda1, Sundaram Kaliappan Pillai1, Shakuntala Viren Shah1.   

Abstract

Cancer of the esophagus and gastroesophageal junction (GEJ) is notorious for its advanced stage at the time of diagnosis with transmural invasion and early lymphatic spread in the majority of the patients. R0 resection is the aim of surgery with curative intent. Regarding the role of lymphadenectomy, as in any other solid organ cancer, there are opposing views. Some surgeons argue that the presence of lymph node involvement equals systemic disease and that survival remains unchanged despite removal of these lymph nodes. For others the presence of lymph node involvement, even at a distance from the primary tumor, justifies an aggressive approach with radical esophagectomy combined with lymphadenectomy. The purpose of this article is to compare standard two field lymph node dissection versus non formal lymph node dissection in carcinoma esophagus. The conclusions are based on the experience with 60 cases of carcinoma esophagus over 2 years. In our opinion total esophagectomy with 2-field lymphadenectomy is the standard surgery for resectable squamous cell carcinoma of esophagus. It improves the lymphnode yield thereby ensuring adequate staging of the disease. It can be performed with acceptable morbidity and mortality as the nonformal lymphadenectomy procedure. Locoregional recurrence following 2 field lymphadenectomy is significantly low as compared to nonformal lymphadenectomy procedure though the distant recurrence rate is same. 2 year disease free survival in this study shows advantage of 2 field lymphadenectomy compared to non formal lymphadenectomy procedure.

Entities:  

Keywords:  2 field lymphadenectomy; Cancer esophagus; Nonformal lymphadenectomy

Year:  2013        PMID: 24426753      PMCID: PMC3890016          DOI: 10.1007/s13193-013-0264-5

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  21 in total

Review 1.  Epidemiologic trends in esophageal and gastric cancer in the United States.

Authors:  Linda Morris Brown; Susan S Devesa
Journal:  Surg Oncol Clin N Am       Date:  2002-04       Impact factor: 3.495

2.  A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma.

Authors:  K M Chu; S Y Law; M Fok; J Wong
Journal:  Am J Surg       Date:  1997-09       Impact factor: 2.565

3.  The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system.

Authors:  Nabil Rizk; Ennapadam Venkatraman; Bernard Park; Raja Flores; Manjit S Bains; Valerie Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2006-12       Impact factor: 5.209

4.  Stage II esophageal carcinoma: the significance of T and N.

Authors:  W A Killinger; T W Rice; D J Adelstein; S V Medendorp; G Zuccaro; T J Kirby; J R Goldblum
Journal:  J Thorac Cardiovasc Surg       Date:  1996-05       Impact factor: 5.209

5.  Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial.

Authors:  M Goldminc; G Maddern; E Le Prise; B Meunier; J P Campion; B Launois
Journal:  Br J Surg       Date:  1993-03       Impact factor: 6.939

6.  Transhiatal esophagectomy: clinical experience and refinements.

Authors:  M B Orringer; B Marshall; M D Iannettoni
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

7.  Staging of carcinoma of the esophagus and cardia: a comparison of different staging criteria.

Authors:  F H Ellis; E Watkins; M J Krasna; G J Heatley; K Balogh
Journal:  J Surg Oncol       Date:  1993-04       Impact factor: 3.454

8.  Radical lymph node dissection for cancer of the thoracic esophagus.

Authors:  H Akiyama; M Tsurumaru; H Udagawa; Y Kajiyama
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

9.  Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.

Authors:  Jan B F Hulscher; Johanna W van Sandick; Angela G E M de Boer; Bas P L Wijnhoven; Jan G P Tijssen; Paul Fockens; Peep F M Stalmeier; Fiebo J W ten Kate; Herman van Dekken; Huug Obertop; Hugo W Tilanus; J Jan B van Lanschot
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

10.  Transhiatal esophagectomy for benign and malignant disease.

Authors:  M B Orringer; B Marshall; M C Stirling
Journal:  J Thorac Cardiovasc Surg       Date:  1993-02       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.